DocMorris AG (XSWX:DOCM) YoY EBITDA Growth: -114.29% (As of Jun. 2025)


XSWX:DOCM DocMorris AG XSWX:DOCM
65 GF Score
Price CHF9.05
GF Value CHF10.58
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is DocMorris AG YoY EBITDA Growth?

DocMorris AG XSWX:DOCM -1.42% 65 YoY EBITDA Growth is -114.29% as of Jun. 2025. GuruFocus rates XSWX:DOCM with a GF Score™ of 65/100 and a GF Value™ of CHF10.58 (Modestly Undervalued). The stock has 8 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. DocMorris AG's YoY EBITDA Growth for the quarter that ended in Jun. 2025 was -114.29%.

DocMorris AG's EBITDA per Share for the six months ended in Jun. 2025 was CHF-0.56.

DocMorris AG YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for DocMorris AG's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DocMorris AG YoY EBITDA Growth Chart

DocMorris AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -483.18 -89.27 37.12 53.74 33.56

DocMorris AG Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.04 49.29 71.48 10.22 -114.29
XSWX:DOCM
65GF Score
DocMorris AG XSWX:DOCM
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DocMorris AG YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

DocMorris AG's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-1.572--2.366)/ | -2.366 |
=33.56 %

DocMorris AG's YoY EBITDA Growth for the quarter that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (Q: Jun. 2025 )
=(EBITDA per Share (Q: Jun. 2025 )-EBITDA per Share (Q: Jun. 2024 )) / | EBITDA per Share (Q: Jun. 2024 )) |
=(-0.555--0.259)/ | -0.259 |
=-114.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -114.29% mean?
DocMorris AG (XSWX:DOCM) has a YoY EBITDA Growth of -114.29% as of Jun. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for DocMorris AG and its competitors.
Is DocMorris AG's YoY EBITDA Growth too high?
DocMorris AG's current YoY EBITDA Growth is -114.29%. Overall, DocMorris AG has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's YoY EBITDA Growth compare to competitors?
DocMorris AG's YoY EBITDA Growth of -114.29% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for DocMorris AG and its competitors. DocMorris AG's current YoY EBITDA Growth is -114.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (XSWX:DOCM) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF10.58, compared to a current price of CHF9.05 — trading 14.5% below its estimated fair value. The current YoY EBITDA Growth is -114.29%. DocMorris AG's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For DocMorris AG (XSWX:DOCM), the current YoY EBITDA Growth is -114.29% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DocMorris AG (XSWX:DOCM) Overvalued in 2026?

Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued. The current stock price of CHF9.05 is trading 14.5% below its estimated GF Value™ of CHF10.58. GuruFocus considers DocMorris AG to be Modestly Undervalued.

Key valuation signals for XSWX:DOCM:

  • YoY EBITDA Growth: -114.29%
  • GF Value™: CHF10.58 vs. price of CHF9.05 (14.5% below fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the XSWX:DOCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DocMorris AG Business Description

Other Exchanges DOCMz:UK0RRB:UKZRE:Germany
Address Walzmuhlestrasse 49, Frauenfeld, CHE, 8500
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
65GF Score

Get the complete analysis for XSWX:DOCM

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF9.05
Price
CHF10.58
GF Value